Pepinformation

Research articles

Longer reads on how specific peptides work, how stable they are, and what the evidence does and does not show.

  1. FOXO4-DRI Preclinical Evidence and Translational Challenges: From Mouse Models to Clinical Reality Safety

    FOXO4-DRI demonstrated selective senolytic activity in the landmark Baar et al. 2017 Cell study, with subsequent independent confirmations in human chondrocytes

  2. FOXO4-DRI Human Trials: Status, Evidence Gaps, and What to Watch (2026) Safety

    As of July 2026, no human trial of FOXO4-DRI has ever been registered or published. ClinicalTrials.gov, the registry where any legitimate trial must appear befo

  3. FOXO4-DRI Safety and Side Effects: What the Evidence Shows (2026) Safety

    In the published mouse studies, FOXO4-DRI caused no reported side effects: treated animals kept their weight, blood counts, and organ markers while senescent ce